AVXL · Anavex Life Sciences Corp.

Track AVXL — free

$2.86 +0.01 (+0.35%) At close · Sep 4

Russell 2000 member Rebalance outlook locked

Market Cap

$265.11M

92.70M

Up next

Next earnings call

Dec 23, 2026 Est · unconfirmed · in 16 wks

Latest filing: 10-Q

filed Aug 28, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 114 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$13.02M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+8.8%

Year over year · more shares

Price change (1Y)

-69.4%

Trailing year

Short interest

15.2%

Latest settlement · 14.3 days to cover

View all 114 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 14.5 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −18%

below

Price vs 50-day avg −0%

below

RSI (14) 45

neutral

MACD trend Negative

52-week position 7%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −14%

trailing

6-month return −39%

trailing

YTD return −20%

this year

Relative strength −54%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $3 › 200d $3 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

15.22% of float · ▼ -2.2% MoM · 14.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

181 holders — mid 3-yr range

Squeeze score 71

high risk · 0–100

Fundamentals

Poor

EPS growth −4%

Y/Y

Free cash flow $-39.0M

Quant / Vol

risk profile

Very High

Volatility 89%

annualized · 1-yr

Max drawdown −77%

past year

ATR 6.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−18% Bearish

Price vs 50-day avg

−0% Neutral

RSI (14)

45 Neutral

MACD trend

Negative Bearish

52-week position

7% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $3 › 200d $3 — 200d above 50d

Institutional flow Distributing

-7% holders QoQ · +24 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

15.22% of float · ▼ -2.2% MoM · 14.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

181 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $2 Now $3 · 7% Range high $10

vs 200-day avg -18% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AVXL Anavex Life Sciences Corp. this stock	$265.11M	-19.7%	—	—	15.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$141.42B	+20.5%	+46.2%	32.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.84B	+7.2%	+20.8%	20.9	2.3%
ARGX Argenx SE	$64.44B	+22.9%	—	—	1.9%
CSLLY Csl Ltd	$59.96B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

181

% held: 41.0%
Net QoQ: -4.2M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

122

View

Short & Settlement

Short Interest Falling

Shares short

14.1M

Days to cover: 14.3d
Change: -320.2K sh

View

Short Volume

Short vol %

45%

As of: Sep 4, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $174
As of: Aug 4, 2026

View

Off-Exchange

Off-exchange %

36.7%

Week of: Jul 27, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Christopher L. Jacobs

Amount: $1.0K–$15.0K
Traded: Dec 12, 2022

View

Financials

Net income (FY)

$-46.4M

EPS diluted: $-0.54

View

Filings

SEC Filings

Latest

8-K

Filed: Sep 2, 2026
This year: 19

View

Proposed Sales

Value

$371.3K

Shares: 73.4K
Filed: Mar 28, 2024

View

Earnings & Events

Earnings Calls

Last call

Aug 25, 2026

View

Performance

	5D	20D	120D	MTD	YTD
AVXL	-4.4%	-14.4%	-39.3%	+2.1%	-19.7%
SPY	+0.1%	-0.4%	+15.1%	+0.4%	+12.9%
vs SPY	-4.5%	-14.0%	-54.4%	+1.7%	-32.6%

Key facts CIK 1314052 CUSIP 032797300 13F (30d) 135 filings 135 filers Visit website

AVXL · Anavex Life Sciences Corp.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance